Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness and safety of intracavernous autologous platelet-rich plasma for erectile dysfunction
2022-002985-34Phase 3Active
- Sponsor
- Boston Medical Group
- Start
- Sep 2022
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial of PRP - RegenKit-BCT-3 Plus in erectile dysfunction (ED) (2 arms), sponsored by Boston Medical Group. Primary endpoint: Change in IIEF-EF at week 21. Started Sep 2022; status: active.
02
Drugs
PRP - RegenKit-BCT-3 Plus
03
Conditions
erectile dysfunction (ED)
Beyond the preview
Go deeper on 2022-002985-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002985-34.